Non-Hodgkins Lymphoma Treatment Market Challenges with Top Players Like Novartis International, Pharmacyclics, Bayer, F. Hoffmann LA Roche, Amgen, Eli Lilly and Company, Nordic Nanovector

Non-Hodgkins Lymphoma (NHL) is a type of cancer that occurs due to abnormal functioning of B or T lymphocytes and leukocytes. However, high cost of NHL drugs and various complications associated with them are acting as a major restraint for the non-Hodgkin lymphoma therapeutics market. Around 80% of the lymphomas arise in developing B cells and the remainder arise in developing T cells. This generally occurs in bone marrow, lymph nodes, spleen, blood and other organs that are part of lymphatic system. Additionally, increasing rituximab resistance and stringent regulatory guidelines are also limiting the growth of the market.

Some cellular therapies such as T cell therapy and CAR T cell therapy are also being developed where patient’s own T cells are used to attack non-Hodgkin's lymphoma cells. The non-Hodgkin lymphoma therapeutics market is segmented by type of treatment and geography. By geography the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. Also various small molecule targeted therapies such as idelalisib and ibrutinib are latest advancements for the treatment of NHL.

Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/547

Rituxan drug which is used to treat NHL and had been a front-line treatment regimen, though there has been an increasing rituximab resistance. Non-Hodgkin’s lymphoma (NHL) varies in their severity, from mild to fatal. According to a new classification of lymphomas published by WHO in 2008, the lymphomas are segmented into four different groups, instead of segregating as Hodgkin’s and Non-Hodgkin’s lymphomas. The list comprises of around 80 various types of lymphomas. To overcome this resistance, there has been various R&D practices that will create space in the market. For instance, Roche, Inc. is conducting phase IIIstudy of Gazyva/Gazyvaro in people with previously untreated with diffuse large B-cell lymphoma.

Key players in the non-Hodgkin’s lymphoma treatment market inlcude Novartis International AG, Pharmacyclics, Inc., Bayer AG, F. Hoffmann LA Roche, Amgen, Inc., Eli Lilly and Company, Nordic Nanovector A/S and AbbVie, Inc. The prominent players are undertaking collaborative strategies for clinical research to yield new drugs which will aid them to gain competitive advantage. For instance, Novartis AG collaborated with Aduro Biotech in 2015 for clinical trial of novel immuno-oncology product such as ADU-S100 that is expected to treat non-Hodgkin’s lymphoma. Also, taking a step ahead, Roche launched a global network of immunotherapy centers named as Immunotherapy Centers of Research Excellence (imCORE) Network in 2016. This network intends to develop potential therapies for non-Hodgkin’s lymphoma by developing drugs that will simulate one’s immune system to fight the disease.

Increase in incidence of NHL will fuel the market

By geography, North America holds the major share in the market because of the high incidence rate of blood cancers in the U.S. According to Leukemia and Lymphoma Society, non-Hodgkin lymphoma is the seventh most common cancer in the U.S. and fifth in the UK. The National Cancer Institute estimated 72,580 new cases and 20,150 deaths in 2016 due to NHL in the U.S. According to the American Cancer Society, 20 cases of NHL, 6 cases of myeloma and 13 cases of leukemia were estimated per 100,000 population in 2014 in the U.S. Moreover, the organization states that, around 6 out of 10 people diagnosed with non-Hodgkin lymphoma are aged 65 and above. Also, NHL is much more common in men than in women.

In-Depth TOC with 30% Discount on Direct Purchase@ https://www.coherentmarketinsights.com/insight/buy-now/547

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.